Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could albumin boost oxygen delivery in sepsis? new trial investigates

NCT ID NCT06556914

Disease control Sponsor: Samsun University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether replacing albumin—a protein in the blood—can improve oxygen delivery in sepsis patients in the intensive care unit. Sepsis is a life-threatening response to infection that can starve organs of oxygen. The study includes adults with sepsis and low albumin levels who have already received standard fluid therapy. Researchers will measure oxygen delivery and track changes in organ function to see if albumin offers an added benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albumin
What this could lead to
If it works, this could point toward a better fluid therapy strategy for sepsis patients in intensive care, potentially improving oxygen delivery and organ function.
What could go wrong
This is a small, early-stage study with only 45 participants, so results may not be conclusive or generalizable. Albumin replacement carries risks like allergic reactions or fluid overload.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

45 people

The number who actually took part.

Started

Nov 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Arterial oxygen saturation (SaO2), hemoglobin (Hb), partial pressure of oxygen in the arterial blood (PaO2) values will be obtained by blood gas measurements. Cardiac output will be calculated from the parasternal long axis window by transthoracic echocardiography and left ventricular outflow tract (LVOT) measurement. LVOT peak velocity measurement (VTI) will be displayed in PulseWave mode through the apical 5-window window. During measurement, the image will be frozen and VTI will be measured from the widest wave. The effect of albumin replacement on the measurements will be evaluated by calculating the ECHO findings, blood gas parameters and SOFA score of the study patients before and after albumin replacement.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Followed up with a diagnosis of sepsis, * over 18 years old * Patients who were diagnosed with hypo-albuminemia after more than 4L/day fluid resuscitation and underwent albumin replacement Exclusion Criteria: * Consent is not given by the patient or his/her guardian, * The initial cause of shock was hypovolemic, cardiogenic or obstructive shock. * Pregnancy or suspected pregnancy * Peripheral limb or severe organ ischemia with peripheral artery disease * Cardiac functions cannot be evaluated optimally by transthoracic echocardiography * Patients who died within the first 24 hours after intensive care admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intensive care unit are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intensive care unit Sepsis

Contacts and locations

Locations

  • Samsun University

    Samsun, Ilkadım, 55100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.